Braveheart Bio, Inc. Common Stock (BRVE) - Total Assets
Based on the latest financial reports, Braveheart Bio, Inc. Common Stock (BRVE) holds total assets worth $126.96 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see how efficiently does Braveheart Bio, Inc. Common Stock generate cash for how efficiently the company converts equity into cash flow.
Braveheart Bio, Inc. Common Stock - Total Assets Trend (2025–2025)
This chart illustrates how Braveheart Bio, Inc. Common Stock's total assets have evolved over time, based on quarterly financial data. See BRVE share price today for real-time trading data and today's change.
Braveheart Bio, Inc. Common Stock - Asset Composition Analysis
Current Asset Composition (December 2025)
Braveheart Bio, Inc. Common Stock's total assets of $126.96 Million consist of 99.9% current assets and 0.1% non-current assets. Explore working capital position of Braveheart Bio, Inc. Common Stock to assess how much short-term liquidity the company maintains relative to its equity base.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 99.8% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2025–2025)
This chart illustrates how Braveheart Bio, Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Braveheart Bio, Inc. Common Stock Competitors by Total Assets
Key competitors of Braveheart Bio, Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Galecto Inc
NASDAQ:GLTO
|
USA | $535.44 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $2.19 Billion |
|
Shanghai Medicilon Inc
SHG:688202
|
China | CN¥2.88 Billion |
|
ABL Bio Inc
KQ:298380
|
Korea | ₩273.72 Billion |
Braveheart Bio, Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 13.63 | 8.11 | - |
| Quick Ratio | 13.63 | 8.11 | - |
| Cash Ratio | 0.00 | 0.00 | - |
| Working Capital | $114.39 Million | $71.07 Million | - |
Braveheart Bio, Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between Braveheart Bio, Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 19.24 |
| Asset Growth Rate (YoY) | 0.0% |
| Total Assets | $89.35 Million |
| Market Capitalization | $1.72 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Braveheart Bio, Inc. Common Stock's assets at a significant premium (19.24x), suggesting investors see substantial growth potential or unique competitive advantages.
Slight Asset Contraction: Braveheart Bio, Inc. Common Stock's assets decreased by 0.0% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Braveheart Bio, Inc. Common Stock (2025–2025)
The table below shows the annual total assets of Braveheart Bio, Inc. Common Stock from 2025 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $89.35 Million | -- |
About Braveheart Bio, Inc. Common Stock
Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. It develops and offers BHB-1893 and HRS-1893, an oral small-molecule cardiac myosin inhibitor (CMI) for the treatment of obstructive HCM and non-obstructive HCM. The company was incorporated in 2024 and is he… Read more